Molecular classification of endometrial cancer implemented in clinical routine practice
.jpg)
Lotte Moens and Annica Pontén
New molecular subtyping based on the GMS560 gene panel has recently been implemented for endometrial cancer at Uppsala University Hospital. This will help guide better personalized treatments for patients with endometrial cancer.
Endometrial cancer is the most common gynecological malignancy and one of the most frequent cancers among women overall. Traditionally, clinicopathological and histological features have been used for risk stratification of disease status in patients with endometrial cancer. Recently, a more objective classification, based on immunohistochemical and molecular markers is being recommended to separate endometrial cancer into four distinct prognostic subtypes, and thereby guide therapeutic decisions.
Clinical Genomics Uppsala has contributed to implementing this molecular subtyping into clinical practice at Uppsala University Hospital – starting routine testing mid-November this year. The classification is based on the GMS560 gene panel, which was developed by Genomic Medicine Sweden and the Clinical Genomics platform.
Patrick Micke
Molecular subtyping of endometrial cancer patients using this panel will provide more accurate prognostic information and help to guide personalized treatment plans. This is a significant advancement for all patients with endometrial cancer, says Patrick Micke, medical director at the Molecular Pathology unit, Academic Laboratory, Uppsala University Hospital.
Read more
Read more about the GMS560 gene panel in a news article from Genomic Medicine Sweden.